Shares of Azenta, Inc. (NASDAQ:AZTA – Get Free Report) have been given a consensus recommendation of “Hold” by the seven analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $41.20.
Several research analysts have weighed in on AZTA shares. Weiss Ratings lowered shares of Azenta from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. Needham & Company LLC increased their price target on shares of Azenta from $33.00 to $37.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th.
Get Our Latest Analysis on Azenta
Azenta Price Performance
Azenta (NASDAQ:AZTA – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.11 by $0.05. The business had revenue of $161.18 million for the quarter, compared to the consensus estimate of $149.31 million. Azenta had a positive return on equity of 1.18% and a negative net margin of 20.63%.
Institutional Trading of Azenta
A number of institutional investors and hedge funds have recently made changes to their positions in AZTA. Integrated Wealth Concepts LLC acquired a new stake in Azenta in the 1st quarter valued at approximately $435,000. Millennium Management LLC increased its holdings in shares of Azenta by 214.8% during the first quarter. Millennium Management LLC now owns 340,580 shares of the company’s stock valued at $11,798,000 after purchasing an additional 232,405 shares during the period. Empowered Funds LLC increased its holdings in shares of Azenta by 10.5% during the first quarter. Empowered Funds LLC now owns 6,482 shares of the company’s stock valued at $225,000 after purchasing an additional 618 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Azenta by 17.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 201,337 shares of the company’s stock valued at $6,974,000 after purchasing an additional 30,492 shares in the last quarter. Finally, Creative Planning bought a new stake in shares of Azenta during the second quarter valued at about $270,000. 99.08% of the stock is currently owned by institutional investors and hedge funds.
Azenta Company Profile
Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.
In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.
See Also
- Five stocks we like better than Azenta
- Deere Earnings: Has the Stock Outrun the Farm Cycle?
- BJ’s Wholesale Club Is Turning Stronger Fundamentals Into a Bullish Setup
- 3 Dividend Stocks Raising Their Payouts as Investors Search for Growth and Income
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
